Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on November 14, 2023, covering events occurring on November 8, 2023, and November 13, 2023. The filing addresses corporate governance changes and executive compensation adjustments.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Director Resignation: Bertrand Velge voluntarily resigned from the Board of Directors effective November 8, 2023. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Executive Compensation Amendment: On November 13, 2023, Chairman and CEO Justin Schreiber entered into a First Amendment to his Employment Agreement.
Guidance, Outlook, and Management Commentary
The filing details specific long-term incentive awards granted to CEO Justin Schreiber under the amended employment agreement:
- Restricted Stock: 50,000 shares of common stock vesting on January 1, 2024.
- Conditional Grant: 50,000 shares of common stock to be granted no later than November 13, 2024, subject to share availability and continued employment.
- Acceleration Provisions: 100% of awards vest immediately in the event of termination without cause, for good reason, or a change in control.
- Forfeiture: Awards may be forfeited for certain misconduct at the Board's discretion.
No forward-looking financial guidance or risk factors specific to future operations were disclosed in this report.
Investor Verification Checklist
- Verify the impact of Bertrand Velge's departure on Board composition and committee assignments.
- Review the attached exhibits (10.2 and 10.3) for full terms of the CEO's employment amendment and restricted stock agreement.
- Confirm the availability of shares within the 2020 Equity and Incentive Plan required for the conditional grant.
- Assess the potential dilution impact of the 100,000 total shares awarded to the CEO.